EMTT (Magnetotransduction Therapy)

EMTT is an emerging therapy with a smaller and less mature evidence base than shockwave therapy, and it should not be considered an established or proven treatment. The strongest current human evidence is a double-blind, placebo-controlled randomised trial of 126 patients with knee osteoarthritis, rotator cuff enthesopathy or lumbar spondyloarthrosis, which reported better physical function and lower pain with EMTT than sham at six and twelve weeks, with mild local side effects. Note that this was a degenerative musculoskeletal-pain study — not a nerve-entrapment study — and a separate scoping review of EMTT for fracture healing found only a handful of small studies supporting it as a possible adjunct. Two cautions matter. First, the clinical literature is still small and concentrated in degenerative joint and tendon conditions, so EMTT's role is best framed as an adjunct, most often alongside shockwave therapy, rather than a stand-alone or first-line treatment. Second, several of the key EMTT studies are linked to the device manufacturer (STORZ Medical) — through supply of the study or sham device or author disclosures — which lowers confidence when the evidence base is small and mostly positive. We weigh that openly, and we will be honest about what is and is not known for your specific condition.